



LEKSELL GAMMA KNIFE® PERFEXION™ SETTING NEW STANDARDS FOR FAST, EFFECTIVE, PRECISE RADIOSURGERY TREATMENTS

PRESS RELEASE

Stockholm, Sweden, June 18, 2007

One year after the first Leksell Gamma Knife® Perfexion™ treatment was performed in Marseille, France, the revolutionary radiosurgery system is exceeding expectations and delivering fast, effective, precise radiosurgery treatments and to date, has treated more than 300 patients. Physicians now have an unprecedented ability to develop and deliver complex treatment plans for patients with metastatic brain tumors.

In June, Washington Hospital Healthcare System, Fremont, CA, became the first U.S. site to treat patients with Leksell Gamma Knife Perfexion. "We treated three patients the first day, and our clinical team was astounded by the ease and speed of the treatments, as well as the ability to conform the dose to the target at a sub-millimeter level," said David Larson, M.D., Ph.D., F.A.C.R., radiation oncologist and co-director of the Gamma Knife program at Washington Hospital.

"The patients we treated had very complex targets or multiple brain metastases, but the treatments only took one to two hours each," said Larson. "In the past, equally conformal treatments would have required well over five hours, even with the most recent Gamma Knife model, which until now, was the fastest and most efficient radiosurgery device available."

Gamma Knife surgery has become the world's most widely used radiosurgery treatment for brain disorders due to its extraordinary accuracy, reduction of excess radiation dose to the body and extensive history and clinical documentation. Unlike other systems designed to treat the whole body, Leksell Gamma Knife is specifically designed to optimize treatment to the head – a fact appreciated by neurosurgeons and patients alike.

Developed in conjunction with leading neurosurgeons, Leksell Gamma Knife Perfexion is:

- **Precise** – thousands of radiation beams converge with a level of accuracy more than 0.5mm, about the thickness of a strand of hair, leaving nearby healthy tissue undamaged.
- **Proven** – With almost 500,000 patients treated worldwide, and thousands of peer-reviewed scientific articles, the system has unmatched clinical experience.
- **Safe** – Unwanted radiation dose to the body is up to 100 times less than that of competing technologies.

Gamma Knife surgery is the only stereotactic radiosurgery system specifically cleared by the FDA for treating metastatic brain tumors. In comparison to linac radiosurgery, peer-reviewed articles and publications prove the tremendous benefit of Gamma Knife surgery for significantly better local tumor control.⁽¹⁾



(1) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05 Journal: Int J Radiat Oncol Biol Phys , Vol: 47, No. 2: pages 291-8. , May 1, 2000 Authors: Shaw E; Scott C; Souhami L; Dinapoli R; Kline R; Loeffler J; Farnan N

Related Links:

www.Elekta.com
www.BrainTumorTreatment.org
www.irsa.org

For further information, please contact:

Media inquiries: Michelle Lee, PR and Advertising Manager, Tel: +1 770-670-2447,
e-mail: michelle.lee@elekta.com

Investor inquiries: Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com.